The candidate, LYT-100, demonstrated anti-fibrotic and anti-inflammatory mechanisms in pre-clinical studies. [...]
Wed, Jul 17, 2019
AMAL's lead vaccine, ATP128, is currently developed for stage IV colorectal cancer and is slated to begin first-in-human trials later this month. [...]
Wed, Jul 17, 2019
Under the terms of the agreement, Sosei Heptares is eligible to receive US$26 million in upfront and near-term payments. [...]
Wed, Jul 17, 2019
NICE has recommended Novartis' Kisqali just three months after its initial rejection. [...]
Wed, Jul 17, 2019

 

The Learning  Partnership